Coronary Heart Disease (CHD)NCT06649305
A Prospective Multicenter Clinical Study： IntracOronary neaR-Infrared Spectroscopy and OptIcal Coherence Tomography for Evaluating Coronary vulNerable Plaque in Patients With diabeTes
An observational study of Coronary Heart Disease (CHD) and Diabetes (DM), run by Shanghai Zhongshan Hospital at 1 site in China.
Trial summary
To evaluate the correlation between maxLCBI4mm/FCTmin(a new index of lipid plaque based on NIRS-OCT technology) and fiber cap thickness , and the prognosis of patients, providing a new quantitative index for early, accurate and comprehensive identification of vulnerable plaques, and exploring preventive measures for… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Coronary Heart Disease (CHD), Diabetes (DM)
- How many people
- 1,516 participants
- Where
- 1 siteChina
- Study dates
- 30 Oct 2024to 30 Sep 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients aged 18 years old or older ，with diabetes requiring an OCT examination or treatment under OCT guidance
Who may be able to join
- 18 years old or older, gender is not limited
- Patients with diabetes who require an OCT examination or treatment under OCT guidance (diabetes definition: active treatment with insulin or oral hypoglycemic agents at admission). For patients with diabetes who are treated with diet only, abnormal fasting blood sugar (>7 mmol/l), blood sugar >11.1 mmol/l at any time, or abnormal glucose tolerance tests based on World Health Organization standards need to be recorded.
- Be able to understand the purpose of clinical research, voluntarily participate can complete the observation as required and sign the informed consent form
- 5: Lesion stenosis greater than or equal to 50% without interventional treatment
- 6: The diameter of the blood vessel in the diseased segment is greater than or equal to 2.5 mm
Who cannot join
- 1: Severe coagulation dysfunction (APTT greater than 3 times the upper limit of the normal range)
- 2: Severe hemodynamic disorder or shock that cannot be corrected
- 3: Patients with renal impairment（eGFR<30 mL/min/1.73m2）
- 4: Severe symptoms of heart failure (NYHA III and above) or left ventricular ejection fraction <30%
- 5: The presence or suspected presence of infective endocarditis or systemic active infection
- 6: Patients with refractory ventricular arrhythmias who have previously undergone coronary bypass transplantation (CABG) or plan to undergo CABG during the study
Show all 12Show fewer
- 7: Patients with serious concurrent diseases such as advanced cancer have a life expectancy of less than 24 months
- 8: Pregnant or lactating women, have a family plan within 24 months or are unwilling to take effective contraceptive measures
- 9: The target vessel has severe calcification or severe tortuosity, which cannot be examined by OCT
- 10: Have participated in other clinical trials or are participating in other drug/device clinical trials within 3 months prior to enrollment and have not met the primary endpoint
- 11: Investigators believe that those who are unnecessary for OCT or not suitable for inclusion in this trial.
- 12: There are multiple lesions in the same blood vessel, and the non-target lesion distance requiring treatment vascular segment is less than 5mm
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Zhongshan Hospital
Shanghai, Shanghai Municipality, 200032
Chenguang Li, Doctor, 86-13816767665, li.chenguang@zs-hospital.sh.cn
Rende Xu, Doctor, 86-15800624206, xu.rende@zs-hospital.sh.cn
About this study
Official title: A Prospective Multicenter Clinical Study：IntracOnary neaR-Infrared Spectroscopy and OptIcal Coherence Tomography for Evaluating Coronary vulNerable Plaque in Patients With diabeTes
To evaluate the correlation between maxLCBI4mm/FCTmin(a new index of lipid plaque based on NIRS-OCT technology) and fiber cap thickness , and the prognosis of patients, providing a new quantitative index for early, accurate and comprehensive identification of vulnerable plaques, and exploring preventive measures for adverse events such as cardiac death and recurrent myocardial infarction caused by vulnerable plaques, so as to improve the long-term prognosis of patients.
- Conditions
- Coronary Heart Disease (CHD), Diabetes (DM)
- Keywords
- near-infrared spectroscopy
- Medical subject headings
- Coronary Disease, Diabetes Mellitus
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Experimental group | NIRS-OCT examination |
What is being measured
The primary outcome is the main question the study is designed to answer.
MACE events in the 24 months after operation
record the MACE events (cardiac death, myocardial infarction, progressive angina, revascularization) after operation in 24 months
Measured: 24 months after operation
Secondary outcomes (2)
The maxLCBI4mm/FCTmin ratio
The maxLCBI4mm/FCTmin ratio is higher than 400/75
Measured: 24 months after operation
The maxLCBI4mm/FCTmin ratio
The maxLCBI4mm/FCTmin ratio can be used as a continuous indicator
Measured: 24 months after operation
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Oct 2024
- Study start30 Oct 2024
- Primary completion15 Jul 2027 (estimated)
- Study completion30 Sep 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Coronary Heart Disease (CHD)Studies of the same condition, open and under way.
- More trials run by Shanghai Zhongshan HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 1,516 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Shanghai Zhongshan Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06649305
- Sponsor's protocol ID
- ORIENT
- Status last verified
- Jan 2026
- First submitted
- 17 Oct 2024
- Last updated
- 12 Feb 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 12 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective Multicenter Clinical Study：IntracOnary neaR-Infrared Spectroscopy and OptIcal Coherence Tomography for Evaluating Coronary vulNerable Plaque in Patients With diabeTes
- ClinicalTrials.gov ID
- NCT06649305
- Acronym / sponsor ID
- ORIENT
- Conditions
- Coronary Heart Disease (CHD), Diabetes (DM)
- Keywords
- near-infrared spectroscopy
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 1,516 participants (estimated)
- Lead sponsor
- Shanghai Zhongshan HospitalUniversity, hospital or other
- Study start
- 30 Oct 2024 (actual)
- Primary completion
- 15 Jul 2027 (estimated)
- Study completion
- 30 Sep 2027 (estimated)
- First posted
- 18 Oct 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To evaluate the correlation between maxLCBI4mm/FCTmin(a new index of lipid plaque based on NIRS-OCT technology) and fiber cap thickness , and the prognosis of patients, providing a new quantitative index for early, accurate and comprehensive identification of vulnerable plaques, and exploring preventive measures for adverse events such as cardiac death and recurrent myocardial infarction caused by vulnerable plaques, so as to improve the long-term prognosis of patients.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Experimental group | – | –NIRS-OCT examination |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients aged 18 years old or older ，with diabetes requiring an OCT examination or treatment under OCT guidance
Key inclusion criteria (5 listed)
- 18 years old or older, gender is not limited
- Patients with diabetes who require an OCT examination or treatment under OCT guidance (diabetes definition: active treatment with insulin or oral hypoglycemic agents at admission). For patients with diabetes who are treated with diet only, abnormal fasting blood sugar (>7 mmol/l), blood sugar >11.1 mmol/l at any time, or abnormal glucose tolerance tests based on World Health Organization standards need to be recorded.
- Be able to understand the purpose of clinical research, voluntarily participate can complete the observation as required and sign the informed consent form
- 5: Lesion stenosis greater than or equal to 50% without interventional treatment
- 6: The diameter of the blood vessel in the diseased segment is greater than or equal to 2.5 mm
Key exclusion criteria (12 listed)
- 1: Severe coagulation dysfunction (APTT greater than 3 times the upper limit of the normal range)
- 2: Severe hemodynamic disorder or shock that cannot be corrected
- 3: Patients with renal impairment（eGFR<30 mL/min/1.73m2）
- 4: Severe symptoms of heart failure (NYHA III and above) or left ventricular ejection fraction <30%
- 5: The presence or suspected presence of infective endocarditis or systemic active infection
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
MACE events in the 24 months after operation
Time frame: 24 months after operation
record the MACE events (cardiac death, myocardial infarction, progressive angina, revascularization) after operation in 24 months
2 secondary outcomes
The maxLCBI4mm/FCTmin ratio
Time frame: 24 months after operation
The maxLCBI4mm/FCTmin ratio
Time frame: 24 months after operation
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Feb 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Coronary Heart Disease (CHD)
Not yet recruiting
Autologous Thymus Transplant in Children With Congenital Heart Disease: A Pilot Study
Congenital Heart Disease (CHD)
Not yet recruiting
Hs-CRP-Guided Colchicine Treatment Targets in Very-High-Risk Patients With Coronary Artery Disease After PCI (TARGET-CHD)
Coronary Artery Disease, Atherosclerotic Cardiovascular Disease (ASCVD)
Active, not recruiting
Learning by Heart: The Effectiveness of an EF Training Program for Pre-schoolers With Critical CHD
Congenital Heart Disease, Executive Dysfunction
Not yet recruiting
UltraTrac for Cardiac Output Monitoring in Congenital Heart Disease
Congenital Heart Disease, Cardiac Output
RecruitingPhase 1/2
Butyric Acid Supplementation for Gut Improvement After Cardiac Surgery in Kids
Congenital Heart Disease (CHD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Coronary Heart Disease (CHD) and Diabetes (DM), run by Shanghai Zhongshan Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 12 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Chenguang Li, Doctor (13816767665, li.chenguang@zs-hospital.sh.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
MACE events in the 24 months after operation (time frame: 24 months after operation). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Feb 2026.